A phase III trial has shown that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy. The IMPRESS trial presented at the ESMO 2014 Congress is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer ...Monday, 29 September 2014
Continuing Tyrosine Kinase Inhibitor Therapy After Resistance Development in Lung Cancer
A phase III trial has shown that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy. The IMPRESS trial presented at the ESMO 2014 Congress is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer ...
No comments:
Post a Comment